GB201506223D0 - Chimeric protein - Google Patents

Chimeric protein

Info

Publication number
GB201506223D0
GB201506223D0 GBGB1506223.5A GB201506223A GB201506223D0 GB 201506223 D0 GB201506223 D0 GB 201506223D0 GB 201506223 A GB201506223 A GB 201506223A GB 201506223 D0 GB201506223 D0 GB 201506223D0
Authority
GB
United Kingdom
Prior art keywords
chimeric protein
chimeric
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1506223.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Priority to GBGB1506223.5A priority Critical patent/GB201506223D0/en
Publication of GB201506223D0 publication Critical patent/GB201506223D0/en
Priority to CA2981846A priority patent/CA2981846A1/en
Priority to PCT/GB2016/051019 priority patent/WO2016166521A1/en
Priority to CN201680021442.1A priority patent/CN107531804A/zh
Priority to AU2016250200A priority patent/AU2016250200B2/en
Priority to US15/565,914 priority patent/US10869911B2/en
Priority to EP16717433.3A priority patent/EP3283526B1/en
Priority to ES16717433T priority patent/ES2749903T3/es
Priority to HK18102740.9A priority patent/HK1243107B/en
Priority to JP2017553230A priority patent/JP6704411B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1506223.5A 2015-04-13 2015-04-13 Chimeric protein Ceased GB201506223D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1506223.5A GB201506223D0 (en) 2015-04-13 2015-04-13 Chimeric protein
JP2017553230A JP6704411B2 (ja) 2015-04-13 2016-04-12 キメラタンパク質
AU2016250200A AU2016250200B2 (en) 2015-04-13 2016-04-12 Chimeric protein
PCT/GB2016/051019 WO2016166521A1 (en) 2015-04-13 2016-04-12 Chimeric protein
CN201680021442.1A CN107531804A (zh) 2015-04-13 2016-04-12 嵌合蛋白
CA2981846A CA2981846A1 (en) 2015-04-13 2016-04-12 Chimeric protein
US15/565,914 US10869911B2 (en) 2015-04-13 2016-04-12 Chimeric protein
EP16717433.3A EP3283526B1 (en) 2015-04-13 2016-04-12 Chimeric protein
ES16717433T ES2749903T3 (es) 2015-04-13 2016-04-12 Proteína quimérica
HK18102740.9A HK1243107B (en) 2015-04-13 2016-04-12 Chimeric protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506223.5A GB201506223D0 (en) 2015-04-13 2015-04-13 Chimeric protein

Publications (1)

Publication Number Publication Date
GB201506223D0 true GB201506223D0 (en) 2015-05-27

Family

ID=53333686

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1506223.5A Ceased GB201506223D0 (en) 2015-04-13 2015-04-13 Chimeric protein

Country Status (10)

Country Link
US (1) US10869911B2 (cg-RX-API-DMAC7.html)
EP (1) EP3283526B1 (cg-RX-API-DMAC7.html)
JP (1) JP6704411B2 (cg-RX-API-DMAC7.html)
CN (1) CN107531804A (cg-RX-API-DMAC7.html)
AU (1) AU2016250200B2 (cg-RX-API-DMAC7.html)
CA (1) CA2981846A1 (cg-RX-API-DMAC7.html)
ES (1) ES2749903T3 (cg-RX-API-DMAC7.html)
GB (1) GB201506223D0 (cg-RX-API-DMAC7.html)
HK (1) HK1243107B (cg-RX-API-DMAC7.html)
WO (1) WO2016166521A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
CN119015448A (zh) * 2018-12-20 2024-11-26 芝加哥大学 与用于癌症疗法的治疗肽相关的方法和组合物
EP4061836A4 (en) * 2019-11-21 2024-02-14 Remedium Bio, Inc. GROWTH FACTOR RESTORATION
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技(香港)有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021198163A1 (en) * 2020-04-01 2021-10-07 Medigene Immunotherapies Gmbh Cd3-fusion protein and uses thereof
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
KR20230016156A (ko) * 2021-07-21 2023-02-01 한국생명공학연구원 신규한 키메릭 항원 수용체 및 이를 발현하는 면역세포
JP2025540894A (ja) * 2022-11-29 2025-12-16 マルコープ・バイオディスカバリーズ・リミテッド 新規cd20タンパク質
PE20260290A1 (es) 2023-03-31 2026-02-10 Abelzeta Inc Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914650D0 (en) * 1999-06-24 1999-08-25 Angyogene Pharmaceuticals Ltd Chimeric proteins mediating targeted apoptosis
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
JP5956342B2 (ja) * 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
EP2920210B1 (en) 2012-11-19 2017-08-30 Baliopharm AG Recombinant bispecific antibody binding to cd20 and cd95
JP2017100947A (ja) 2014-03-31 2017-06-08 株式会社オーダーメードメディカルリサーチ 目的抗原に対する抗体の作製方法

Also Published As

Publication number Publication date
AU2016250200A1 (en) 2017-10-26
US20180169189A1 (en) 2018-06-21
CA2981846A1 (en) 2016-10-20
AU2016250200B2 (en) 2020-08-13
JP6704411B2 (ja) 2020-06-03
US10869911B2 (en) 2020-12-22
WO2016166521A1 (en) 2016-10-20
EP3283526A1 (en) 2018-02-21
ES2749903T3 (es) 2020-03-24
JP2018512154A (ja) 2018-05-17
CN107531804A (zh) 2018-01-02
EP3283526B1 (en) 2019-09-04
HK1243107B (en) 2020-05-08

Similar Documents

Publication Publication Date Title
ZA201704231B (en) Chimeric protein
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
GB201509413D0 (en) Fusion protein
SG11201704010UA (en) Fibroin-derived protein composition
IL252696A0 (en) protein production
ZA201906235B (en) Csf1r-based chimeric proteins
GB201415344D0 (en) Protein
GB201504691D0 (en) Fusion protein
HUE067090T2 (hu) Fehérje
GB201505306D0 (en) Chimeric polypeptides
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
SG11201606501PA (en) Nanobody-fluorescent protein fusion
ZA201801394B (en) Fusion protein
GB201513033D0 (en) Proteins
PL3099793T3 (pl) Białko
IL268170A (en) vsig8-based chimeric proteins
EP3204427A4 (en) Chimeric proteins
GB201522610D0 (en) Protein
GB201515337D0 (en) Protein Expression
GB201515744D0 (en) Proteins
GB201503778D0 (en) Proteins
GB201414371D0 (en) Protein modification
AU2014904028A0 (en) Chimeric proteins

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)